TITLE

THE IPO 100

PUB. DATE
March 2004
SOURCE
Investment Dealers' Digest;3/8/2004, Vol. 70 Issue 10, p31
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Measures the average price of initial public offerings filed by companies in the U.S. as of March 8, 2004. Linktone; Kinetic Concepts; Cherokee International; Dynavax Technologies; Corgentech.
ACCESSION #
12460771

 

Related Articles

  • THE IPO 100.  // Investment Dealers' Digest;3/1/2004, Vol. 70 Issue 9, p45 

    Presents data on initial public offerings. Kinetic Concepts Inc.; Cherokee International LLC; Dynavax Technologies Corp.; Bristol West Holdings; AlphaSmart.

  • THE IPO 100.  // Investment Dealers' Digest;3/15/2004, Vol. 70 Issue 11, p47 

    Presents a chart of 100 initial public offerings in the U.S., compiled as of March 2004. TOM Online; Kinetic Concepts; Cherokee International; Dynavax Technologies; CEA Acquisition; Corgentech; Bristol West Holdings; Asset Acceptance; CrossTex Energy; Luminant Mortgage Capital.

  • IPOs IN THE U.S.  // Investment Dealers' Digest;2/23/2004, Vol. 70 Issue 8, p42 

    Presents charts of initial public offerings (IPO) in the United States. Scheduled IPO of Kinetic Concepts and Dynavax Technologies; IPO filed by Strategic Hotel Capital; K-Sea Transportation's emergence from the quiet period.

  • AFTERMARKET PERFORMANCE.  // Investment Dealers' Digest;3/8/2004, Vol. 70 Issue 10, p33 

    Describes the initial 2004 public offering performance issued by several companies. CrossTex Energy; Eyetech Pharmaceuticals; Kinetic Concepts; Government Properties Trust; Symbion.

  • Dynavax Prices $39M Offering as Heplisav Finishes Phase III.  // Bioworld Week;11/1/2010, Vol. 18 Issue 44, p5 

    The article announces that U.S.-based biotechnology company, Dynavax Technologies Corp., has priced 39.1 million dollars worth of public stock offering amidst the near completion of its hepatitis B vaccine, Heplisav.

  • Financings Roundup.  // BioWorld Today;11/4/2011, Vol. 22 Issue 215, p4 

    The article reports on the 60 million U.S. dollars public offering of Dynavax Technoligies Corp. of Berkeley, California.

  • Financings Roundup.  // BioWorld Today;11/10/2011, Vol. 22 Issue 219, p3 

    The article reports on the completion of Dynavax Technologies Corporation's public offering of shares of common stock, the proceeds of which will be used in funding for the launch of Hepsilav hepatitis B vaccine.

  • Dynavax Raises $44M to Push Phase III HBV Vaccine Heplisav. Morrison, Trista // BioWorld Today;4/14/2010, Vol. 21 Issue 71, p1 

    The article announces the plan of Dynavax Technologies Corp. to raise 44 million U.S. dollars. With this, the firm intends to make a public offering of stock and warrants. Proceeds will be used for the Phase III trials of its hepatitis B vaccine Heplisav and for its license application filing in...

  • Private consortium set to pay $6.3 billion for Kinetic Concepts. PEDERSEN, AMANDA // Medical Device Daily;7/14/2011, Vol. 15 Issue 130, p1 

    The article reports on the offer of a group of private equity investors to purchase Kinetic Concepts (KCI) for 68.50 U.S. dollars a share in a cash deal amounting to 6.3 billion U.S. dollars, including the outstanding debt of the company. KCI reportedly went public in early 2004 through an...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics